Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | MTOR | P42345 | 1/20 | 0.62 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.62 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.62 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | ST6GAL1 | P15907 | 3/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL800395 | 1.00 | NT5E (0.65) | NT5ELMNATHRBMTORMDM2 | |
| SCHEMBL800216 | 1.00 | NT5E (0.65) | NT5ELMNATHRBMTORMDM2 | |
| SCHEMBL13134657 | 1.00 | NT5E (0.65) | NT5ELMNATHRBMTORMDM2 | |
| SCHEMBL800348 | 1.00 | NT5E (0.65) | NT5ELMNATHRBMTORMDM2 | |
| SCHEMBL13190277 | 1.00 | NT5E (0.65) | NT5ELMNATHRBMTORMDM2 | |
| SCHEMBL800434 | 1.00 | NT5E (0.65) | NT5ELMNATHRBMTORMDM2 | |
| Phosphoric Acid SCHEMBL16859831 | 0.95 | NT5E (0.67) | NT5ELMNATHRBMTORMDM2 | |
| SCHEMBL15160625 | 0.90 | NT5E (0.54) | NT5ELMNATHRBMTORMDM2 | |
| SCHEMBL13173256 | 0.90 | NT5E (0.57) | NT5ELMNATHRBMTORMDM2 | |
| SCHEMBL13173631 | 0.90 | NT5E (0.57) | NT5ELMNATHRBMTORMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 654 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637673-B2 | Compositions and methods for splicing modulation OF UNC13A | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-26 | — | — | US | claimed |
| US-12612630-B2 | Compositions and methods for splicing modulation of UNC13A | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-04-28 | — | — | US | claimed |
| US-20250304964-A1 | COMPOSITIONS AND METHODS FOR SPLICING MODULATION OF UNC13A | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-10-02 | — | — | US | claimed |
| US-20250283083-A1 | COMPOSITIONS AND METHODS FOR SPLICING MODULATION OF UNC13A | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-09-11 | — | — | US | claimed |
| EP-4605009-A2 | GLYCAN CONJUGATE COMPOSITIONS AND METHODS | GanNA Bio, Inc. (US) | 2025-08-27 | — | — | EP | claimed |
| US-20250242035-A1 | GLYCAN CONJUGATE COMPOSITIONS AND METHODS | GANNA BIO, INC. | 2025-07-31 | — | — | US | claimed |
| WO-2025137510-A1 | ADIPONECTIN MRNA COMPOSITIONS AND METHODS OF USING THE SAME | TRUSTEES OF TUFTS COLLEGE (US) | 2025-06-26 | — | — | WO | claimed |
| US-20240376473-A1 | ANTISENSE COMPOUND FOR MODULATING WFDC2 EXPRESSION | QMINE CO., LTD. (KR) | 2024-11-14 | — | — | US | claimed |
| WO-2024228118-A1 | MIRNA-485 INHIBITORS | BIORCHESTRA CO., LTD. (KR) | 2024-11-07 | — | — | WO | claimed |
| WO-2024201525-A2 | ANTISENSE OLIGONUCLEOTIDES, METHODS AND USE THEREOF | KOSHKEY SCIENCES PVT LTD (IN) | 2024-10-03 | — | — | WO | claimed |
| WO-2014144761-A2 | INCREASING SPECIFICITY FOR RNA-GUIDED GENOME EDITING | THE GENERAL HOSPITAL CORPORATION (US) | 2014-09-18 | — | — | WO | claimed |
| EP-2600901-A2 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF | Moderna Therapeutics, Inc. (US) | 2013-06-12 | — | — | EP | claimed |
| EP-2221376-B1 | Antisense modulation of superoxide dismutase 1, soluble expression | ISIS PHARMACEUTICALS INC (US) | 2012-11-21 | — | — | EP | claimed |
| US-20120065252-A1 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2012-03-15 | — | — | US | claimed |
| WO-2012019168-A2 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2012-02-09 | — | — | WO | claimed |
| US-20080027019-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | ISIS PHARMACEUTICALS, INC. (US) | 2008-01-31 | — | — | US | claimed |
| US-7235653-B2 | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein | ISIS PHARMACEUTICALS, INC. (US) | 2007-06-26 | — | — | US | claimed |
| US-20040235164-A1 | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein | ISIS PHARMACEUTICALS, INC. | 2004-11-25 | — | — | US | claimed |
| US-6545162-B1 | Solid phase biosynthesis of viricide antibiotic | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2003-04-08 | — | — | US | claimed |
| US-6174868-B1 | ANTISENSE OLIGONUCLEOTIDES WHICH ARE COMPLEMENTARY TO AND HYBRIDIZABLE WITH HCV RNA; INHIBITS THE FUNCTION OF THE GENOME AND MESSENGER RNA; PROPHYLAXIS AND THERAPY; MEDICAL DIAGNOSIS/DETECTION OF THE VIRUS AND ASSOCIATED DISEASE | ISIS PHARMACEUTICALS, INC. | 2001-01-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637673-B2 | Compositions and methods for splicing modulation OF UNC13A | NSUN2, UPF1, METTL16 | NT5E 139/4885LMNA 335/4885THRB 2612/4885 |
| US-20040235164-A1 | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein | CD2BP2, MICA, CD74 | NT5E 78/4885LMNA 3875/4885THRB 3651/4885 |
| US-20080027019-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | CD2BP2, MICA, CD74 | NT5E 78/4885LMNA 3875/4885THRB 3651/4885 |
| US-20250242035-A1 | GLYCAN CONJUGATE COMPOSITIONS AND METHODS | SIGLEC7, SIGLEC9, ENGASE | NT5E 958/4885LMNA 2959/4885THRB 1350/4885 |
| US-12612630-B2 | Compositions and methods for splicing modulation of UNC13A | UPF1, NSUN2, NSUN3 | NT5E 94/4885LMNA 291/4885THRB 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.